Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Oleg V, Tcheremissine"'
Autor:
Charmi Patel, Oleg V Tcheremissine, Timothy Hetherington, Carmela Benson, Kruti Joshi, Constance Krull, Dee Lin, Pooja Palmer, Rohan Mahabaleshwarkar, Jesse Fishman, Todd Blair
Publikováno v:
Advances in Therapy
Introduction Previous evidence demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated the impact of initiating once-monthly paliperidone palmitate (PP1M) on hea
Autor:
Oleg v Tcheremissine, Lori M Lieving
Publikováno v:
Therapeutics and Clinical Risk Management, Vol 2009, Iss default, Pp 367-369 (2009)
Oleg v Tcheremissine1, Lori M Lieving21Department of Psychiatry, Behavioral Health Center – Carolinas Medical Center, Charlotte, NC, USA; 2Carolinas College of Health Sciences, Charlotte, NC, USAAbstract: Attention-deficit/hyperactivity disorder (A
Externí odkaz:
https://doaj.org/article/d40bef0db7af40eda5b0270822bf6cc0
Autor:
Rohan, Mahabaleshwarkar, Dee, Lin, Kruti, Joshi, Jesse, Fishman, Todd, Blair, Timothy, Hetherington, Pooja, Palmer, Charmi, Patel, Constance, Krull, Oleg V, Tcheremissine
Publikováno v:
The journal of mental health policy and economics. 24(2)
Schizophrenia is one of 15 major causes of disability worldwide and is responsible for more than USD 150 billion in annual healthcare costs in the United States. Although the burden of schizophrenia as measured by healthcare resource utilization (HRU
Publikováno v:
Innovations in clinical neuroscience. 15(5-6)
Objective: Given the growing public health importance of measuring the change in mental health stigma over time, the goal of this study was to demonstrate the potential for using machine learning as a tool to analyze patterns of social stigma as a co
Autor:
Oleg V, Tcheremissine, James C, Rachal
Publikováno v:
Innovations in clinical neuroscience. 14(3-4)
Publikováno v:
Innovations in clinical neuroscience. 13(7-8)
Publikováno v:
Expert Opinion on Investigational Drugs. 21:7-14
Schizophrenia is a chronic disorder associated with positive and negative symptoms and wide-ranging deficits in neurocognitive function. Neurocognitive deficits are considered to be the core pathophysiological symptoms of the illness. Neurocognitive
Autor:
Oleg V Tcheremissine
Publikováno v:
Expert Opinion on Drug Safety. 7:739-748
The abuse and diversion of pharmacological agents with CNS mechanisms of action is an important concern from governmental, regulatory, public health and safety perspectives. In recent years, there have been an increased number of reports concerning t
Publikováno v:
Journal of Psychopharmacology. 22:144-152
Experimental and clinical studies have supported a relationship between γ-aminobutyric acid (GABA) and aggressive behavior in non-humans and humans. Tiagabine is a GABA uptake inhibitor that has been shown to produce acute behavioral effects in anim
Publikováno v:
Addictive Behaviors. 32:977-990
The present study examined two behavioral processes - response perseveration and response adaptation - in adolescents who were heavy marijuana smokers and control adolescents. Testing took place in a controlled laboratory setting, using customized so